Roche's Q1 Saved By Cancer Drugs Perjeta And Kadcyla

A strong uptake of new cancer medicines helped Roche to limit a decline in first-quarter sales and the Swiss company confirmed a forecast for higher earnings this year. Roche Holding AG said currency movements, the loss of exclusivity on chemotherapy drug Xeloda and falling sales of hepatitis medicine Pegasys combined to pull sales down 1 percent. Excluding the impact of currency swings, sales grew 5 percent, thanks partly to the strong performance of its cancer drugs and rheumatoid arthritis treatment RoActemra.

Help employers find you! Check out all the jobs and post your resume.